Table 1.
Demographics and baseline disease characteristics.
| Characteristics | (N=54) |
|---|---|
| Age, no. (%) | |
| <65 yr | 46 (85) |
| ≥65 yr | 8 (15) |
| Mean (SD) | 57 (8) |
| Median (range) | 58 (53 to 62) |
| Sex, no. (%) | |
| Male | 28 (52) |
| Female | 26 (48) |
| ISS stage, no. (%) | |
| I | 7 (13) |
| II | 23 (43) |
| III | 24 (44) |
| Bone marrow monoclonal plasma cell ratio (%) | |
| <50% | 41 (76) |
| ≥50% | 13 (24) |
| Type of myeloma, no. (%) | |
| IgG | 27 (50) |
| IgA | 7 (13) |
| IgD | 4 (7) |
| IgM | 1 (2) |
| Light chain | 11 (20) |
| Kappa | 7 (13) |
| Lambda | 4 (7) |
| Nonsecretory | 4 (7) |
| Time from initial MM diagnosis, months | |
| Mean (SD) | 40 (30) |
| Median (range) | 30 (18 to 61) |
| Number of prior lines of therapy, no | |
| Mean (SD) | 4 (2) |
| Median (range) | 4 (3 to 5) |
| Autologous stem cell transplantation, no. (%) | 15 (28) |
| Prior therapies, no. (%) | |
| Proteasome inhibitors | 53 (98) |
| Bortezomib | 52 (96) |
| Ixazomib | 15 (28) |
| Immunomodulatory agents | 53 (98) |
| Lenalidomide | 34 (63) |
| Pomalidomide | 3 (6) |
| Thalidomide | 38 (70) |
| Proteasome inhibitors+immunomodulatory agents | 52 (96) |